SFEBES2014 Poster Presentations Neoplasia, cancer and late effects (25 abstracts)
Pre-clinical assessment of the impact of Erlotinib on adrenocortical cancer cells proliferation
Dorota Dworakowska 1, , Dorota Dudka 1, , Gregory Weitsman 3 , Peter King 4 , Harshini Katugampola 4 , Márta Korbonits 4 , Klaus-Martin Schulte 1 , Salvador Diaz-Cano 1 , Alan McGregor 1 , Ashley B Grossman 5 , Simon Aylwin 1 , Krzysztof Sworczak 2 & Tony Ng 3
1Department of Endocrinology, Kings College Hospital, London, UK; 2Department of Endocrinology and Internal Medicine, Medical University of Gdansk, Gdansk, Poland; 3Richard Dimbleby Department of Cancer Research, Kings College London, London, UK; 4Department of Endocrinology, Barts and the London Hospital, London, UK; 5Oxford Centre for Endocrinology, Diabetes and Metabolism, Oxford, UK.
Introduction: Adrenocortical carcinoma (ACC) has a poor prognosis and limited therapeutic options. The epidermal growth factor receptor (EGFR) expression was found to be a good discriminator between malignant and benign adrenal tumours, but was mutated only in 3–10% of ACC cases.
Aim: The aim of this study was to assess the effect of inhibition of EGFR with targeted therapies, i.e. Erlotinib (with and without EGF stimulation) on ACC cell proliferation in a pre-clinical setting.
Material and methods: Proliferation of ACC cells (H295R cell line and primary adrenocortical tumour culture) was assessed by Alamar blue assay after 24, 48, and 72 h of incubation with inhibitor at presence or absence of EGF. The expression and activation/inhibition of EGFR, and downstream signalling (Akt, Erk1/2, and mTORC1) was detected by western blot analysis.
Results: Despite the fact that the expression of EGFR was below the detection level using western blotting, activation of downstream signalling by EGF was shown by activation of Erk1/2 and Akt proteins. Erlotinib decreased cell proliferation rate after 24, 48, and 72 h of treatment, and the effect was enhanced in the presence of EGF. These effects were observed both in H295R cell line and in primary tumour culture.
Conclusions: Erlotinib alone inhibits cell proliferation and acts more potently if used jointly with EGF. We hypothesize that this effect may be associated with the change in cell metabolism caused by EGF. Therapy with anti-EGFR agents may be successful in ACC patients but requires further study.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more